B. Riley Lowers Earnings Estimates for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at B. Riley lowered their Q3 2025 earnings estimates for shares of Eton Pharmaceuticals in a report released on Thursday, May 15th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings per share of $0.10 for the quarter, down from their prior forecast of $0.11. B. Riley currently has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' FY2027 earnings at $1.91 EPS, FY2028 earnings at $2.29 EPS and FY2029 earnings at $2.52 EPS.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

ETON has been the subject of several other reports. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. HC Wainwright restated a "buy" rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

ETON traded up $0.64 on Monday, reaching $20.24. 490,717 shares of the company's stock were exchanged, compared to its average volume of 194,179. Eton Pharmaceuticals has a twelve month low of $3.18 and a twelve month high of $21.48. The company's 50 day moving average is $15.01 and its 200-day moving average is $14.08. The company has a market cap of $542.80 million, a price-to-earnings ratio of -92.00 and a beta of 1.22.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Baader Bank Aktiengesellschaft purchased a new position in shares of Eton Pharmaceuticals in the fourth quarter valued at $373,000. Anchor Capital Advisors LLC purchased a new position in Eton Pharmaceuticals in the 4th quarter valued at about $805,000. Raymond James Financial Inc. acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at about $147,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Eton Pharmaceuticals by 230.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock worth $2,862,000 after acquiring an additional 149,864 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC lifted its stake in shares of Eton Pharmaceuticals by 11.3% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company's stock worth $1,705,000 after acquiring an additional 13,009 shares in the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.